

# Supplemental Table S1

Major adverse events during the clinical trial

Events	Number of patients (%)	Number of patients (%)
	Control group (n = 24)	Ipragliflozin group (n = 24)
Any adverse event	20 (83.3)	21 (87.5)
Hypoglycemia	10 (41.7)	13 (54.2)
Exanthema/skin itching	4 (16.7)	10 (41.7)
Muscle/joint pain	7 (29.2)	5 (20.8)
Upper respiratory infection	4 (16.7)	5 (20.8)
Urinary tract infection	3 (12.5)	4 (16.7)
Dehydration	3 (12.5)	4 (16.7)
Genital itching	0 (0)	3 (12.5)
Liver dysfunction	0 (0)	1 (4.2)
Cholecystitis/Cholangitis	0 (0)	2 (8.3)
Orthostatic hypotension	0 (0)	1 (4.2)
Candida vaginitis	0 (0)	1 (4.2)
Other	7 (29.2)	10 (41.7)

Hypoglycemia, dehydration, urinary tract infection, exanthema and orthostatic hypotension were predefined as adverse events.